BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from a Phase 1b trial evaluating the company’s investigational toll-like receptor 7 (TLR7) agonist vesatolimod as part of a human immunodeficiency virus (HIV) cure research program. These finding

Joerns Healthcare, a leading wound solutions provider, is proud to announce it has signed a partnering agreement with Healiant to advance its mission of developing and delivering best-in-class wound care services and products to the entire care continuum.

The National Osteoporosis Foundation’s Online Community, hosted by Inspire, now connects more than 50,000 members. NOF’s online community is a safe place where patients and caregivers affected by osteoporosis can come together to share helpful advice and support one another. The community has grown rapidly since launching in Octobe

The coronavirus pandemic shows the effect of government interference with free-market solutions, states the Association of American Physicians and Surgeons (AAPS). Testing is widely available in South Korea, which has more of a free market, while testing remains mostly unavailable in the United States. Convenient drive-through testing in South Korea has enabled it to react quickly and effectively to an ominous outbreak there. But for week

Viracor Eurofins, in accordance with the FDA Emergency Use Authorization Guidance, announces it will start testing specimens for Coronavirus SARS-CoV-2 RT-PCR as of March 13, 2020.

MFG Chemical, a global leader in specialty and custom chemical manufacturing, announces that Dr. Jonathan O’Dwyer has joined the company as VP Commercial Operations.

Venus Concept Inc. (“Venus Concept” or the “Company”) (NASDAQ: VERO), a global medical aesthetic technology leader, announced that fourth quarter and fiscal year 2019 financial results will be released after the market closes on Monday, March 30.

Sophiris Bio Inc. (NASDAQ: SPHS) (the “Company” or “Sophiris”), today announced that on March 10, 2020, the Nasdaq Office of General Counsel notified the Company that the Nasdaq Hearing Panel (“Panel”) had determined to delist the Company’s shares from The Nasdaq Stock Market LLC (“Nasdaq”), and that trading in the Company’s common shares will be suspended effective at the open of business on March 12, 2020.

Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) today reported financial results for the fourth quarter and year ended December 31, 2019. Loss from operations for the three months and year ended December 31, 2019 was $5.4 million and $23.3 million.

Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for mobile handset and wireless devices, today announced financial results for the fourth quarter and fiscal year ended December 31, 2019 and provided a business update.